Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions
Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions
复制标题
DOI：
10.1128/jcm.00216-07
复制
发表时间：
2007-10-01
影响因子：
9.4
通讯作者：
Wang, Sophia S.
中科院分区：
文献类型：
--
作者：
Gravitt, Patti E.;van Doorn, Leen Jan;Wang, Sophia S.
确定宫颈组织中的型特异性人乳头瘤病毒（HPV）感染对于了解宫颈肿瘤的发病机制和评估具有有限型特异性谱的预防性疫苗的有效性非常重要。我们比较了146个匹配的脱落细胞和福尔马林固定的组织标本收集的宫颈阴道灌洗（CVL）在90天内从组织学确诊的宫颈上皮内病变（CIN）的妇女HPV DNA检测结果。采用MY 09/11 L1共有引物PCR方法，然后进行斑点杂交，对CVL标本进行HPV分型。使用SPF，0线探针测定HPV检测系统对组织标本进行HPV分型。在组织中有CIN证据的146个样本对中，91.8%的组织和细胞样本中的一种或多种HPV类型呈阳性。组织切片中HPV阴性的可能性更大（P < 0.01）。直接从组织切片分型解决了脱落细胞中检测到的多种感染，只有46.9%的病例为单一HPV类型。联合使用两种标本类型将病变归因于HPV 16型（HPV-16）和/或-18导致43.1%归因于两种标本类型的HPV-16和/或-18，19.9%归因于一种但不是两种标本类型的HPV-16和/或-18。将宫颈病变明确归因于单一的、特定的HPV类型仍然是一个困难的命题。使用多种标本类型或开发高度敏感和稳健的原位杂交HPV检测方法来评估病变归因于HPV类型的确定性，可能会为未来的努力提供见解，包括HPV疫苗试验。
Defining type-specific human papillomavirus (HPV) infections within cervical tissues is important for understanding the pathogenesis of cervical neoplasia and assessing the effectiveness of prophylactic vaccines with limited type-specific spectra. We compared HPV DNA-testing results from 146 matched exfoliated-cell and formalin-fixed-tissue specimens collected by cervicovaginal lavage (CVL) within 90 days of each other from women with histologically confirmed cervical intraepithelial lesions (CIN). The CVL specimens were HPV typed using a MY09/11 L1 consensus primer PCR method followed by dot blot hybridization. The tissue specimens were HPV typed using an SPF,0 line probe assay HPV detection system. Of the 146 specimen pairs with evidence of CIN in the tissue, 91.8% were positive for one or more HPV types in both the tissue and cellular specimens. Tissue sections were more likely to be HPV negative (P < 0.01). Typing directly from tissue sections resolved multiple infections detected in exfoliated cells to a single HPV type in only 46.9% of cases. Combined use of both specimen types to attribute lesions to HPV type 16 (HPV-16) and/or -18 led to 43.1% attributed to HPV-16 and/or -18 by both specimen types and 19.9% attributed to HPV-16 and/or -18 by one, but not both, specimen types. Unambiguous attribution of cervical lesions to a single, specific HPV type remains a difficult proposition. Use of multiple specimen types or the development of highly sensitive and robust in situ hybridization HPV-testing methods to evaluate the certainty of attribution of lesions to HPV types might provide insights in future efforts, including HPV vaccine trials.